Predictive factors for the outcome of allogeneic transplantation in patients with MDS stratified according to the revised IPSS-R

  • Matteo G. Della Porta
    Department of Hematology Oncology, Fondazione Istituto Di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo, Pavia, Italy;
  • Emilio Paolo Alessandrino
    Department of Hematology Oncology, Fondazione Istituto Di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo, Pavia, Italy;
  • Andrea Bacigalupo
    Department of Hematology, San Martino Hospital, Genova, Italy;
  • Maria Teresa van Lint
    Department of Hematology, San Martino Hospital, Genova, Italy;
  • Luca Malcovati
    Department of Hematology Oncology, Fondazione Istituto Di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo, Pavia, Italy;
  • Cristiana Pascutto
    Department of Hematology Oncology, Fondazione Istituto Di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo, Pavia, Italy;
  • Michele Falda
    Department of Hematology, San Giovanni Battista Hospital, Turin, Italy;
  • Massimo Bernardi
    Hematology and Bone Marrow Transplant Unit, Department of Oncology, San Raffaele Scientific Institute, Milan, Italy;
  • Francesco Onida
    Hematology and Bone Marrow Transplantation Center, Fondazione Istituto Di Ricovero e Cura a Carattere Scientifico Ospedale Maggiore Policlinico and University of Milan, Milan, Italy;
  • Stefano Guidi
    Division of Hematology and Bone Marrow Transplantation, Azienda Ospedaliera Universitaria Careggi, Florence, Italy;
  • Anna Paola Iori
    Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy;
  • Raffaella Cerretti
    Rome Transplant Network, Department of Hematology, Stem Cell Transplant Unit, Policlinico Tor Vergata, Rome, Italy;
  • Paola Marenco
    Department of Hematology Oncology, Ospedale Niguarda Ca' Granda, Milan, Italy;
  • Pietro Pioltelli
    Division of Hematology and Transplant Unit, Ospedale San Gerardo, Monza, Italy;
  • Emanuele Angelucci
    Hematology and Bone Marrow Transplantation Unit, Ospedale Oncologico di Riferimento Regionale Armando Businco, Cagliari, Italy; and
  • Rosi Oneto
    Department of Hematology, San Martino Hospital, Genova, Italy;
  • Francesco Ripamonti
    Department of Hematology Oncology, Fondazione Istituto Di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo, Pavia, Italy;
  • Paolo Bernasconi
    Department of Hematology Oncology, Fondazione Istituto Di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo, Pavia, Italy;
  • Alberto Bosi
    Division of Hematology and Bone Marrow Transplantation, Azienda Ospedaliera Universitaria Careggi, Florence, Italy;
  • Mario Cazzola
    Department of Hematology Oncology, Fondazione Istituto Di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo, Pavia, Italy;
  • Alessandro Rambaldi
    Hematology and Bone Marrow Transplant Units of Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy

抄録

<jats:title>Key Points</jats:title> <jats:p>Disease relapse is a common cause of failure of allogeneic hematopoietic stem cell transplantation in patients with advanced MDS. High IPSS-R prognostic risk category and monosomal karyotype are independent predictors of relapse after allogeneic transplantation in MDS.</jats:p>

収録刊行物

  • Blood

    Blood 123 (15), 2333-2342, 2014-04-10

    American Society of Hematology

被引用文献 (9)*注記

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ